Trobix Bio
Phage-based Antimicrobial Resistance-sensitizing Solutions
Company Overview
Snapshot
Founded in March 2019 by Adi Elkeles, Trobix Bio operates with 1–10 employees. The company has raised $8.2 million across four funding rounds from two investors. In March 2023, Trobix Bio secured its latest funding round.
Business overview
Trobix Bio is an Israeli biotech company focused on human microbiome research. The company utilizes its TBX™ technology platform, which integrates CRISPR, phage, and synthetic biology, to reprogram specific activities in targeted microbiome bacteria. This approach is used to develop orally administered precision oncology therapeutics. Trobix Bio's preclinical products, TBX201 and TBX301, aim to mitigate severe diarrhea and colitis in cancer patients undergoing irinotecan or checkpoint inhibitor treatments, respectively, targeting cumulative markets exceeding $4 billion. The company operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.
Strategic signal
In March 2023, Trobix Bio raised $3 million from Chartered Group to advance its precision microbiome oncology therapeutics. This funding underscores continued investor confidence in the company's innovative approach to leveraging the microbiome for cancer treatment, signaling potential for further development in its preclinical pipeline and validation of its TBX™ technology platform.
Company Intelligence Q&A
- What is Trobix Bio's primary focus?
- Trobix Bio is an Israeli biotech company focused on pioneering the field of human microbiome via its TBX™ technology platform, utilizing CRISPR, phage, and synthetic biology to re-program specific activities in targeted microbiome bacteria and develop orally administered precision oncology therapeutics.
- When was Trobix Bio founded?
- Trobix Bio was founded in March 2019.
- Which investors participated in Trobix Bio's March 2019 seed funding round?
- In March 2019, Trobix Bio received seed funding from Momentum Fund and The Chartered Group.
- What was a significant funding event for Trobix Bio in 2023?
- In March 2023, Trobix Bio raised $3 million from Chartered Group to advance its precision microbiome oncology therapeutics.
- What are Trobix Bio's key preclinical products?
- Trobix Bio's key preclinical products, TBX201 and TBX301, are being developed to reduce severe diarrhea and colitis in patients receiving irinotecan or checkpoint inhibitors, respectively.